• +1-646-491-9876
    • +91-20-67278686

    Search

    Sicca Syndrome Pipeline Review H1 2017

    Sicca Syndrome Pipeline Review H1 2017

    • Report Code ID: RW0001858651
    • Category Pharmaceuticals
    • No. of Pages 104
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides an overview of the Sicca Syndrome (Sjogren) (Immunology) pipeline landscape.

    Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling and stiffness. Predisposing factors include age, sex and rheumatic disease.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Sicca Syndrome (Sjogren) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren) (Immunology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Sicca Syndrome (Sjogren) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 4, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

    Sicca Syndrome (Sjogren) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Sicca Syndrome (Sjogren) (Immunology) .
    - The pipeline guide reviews pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Sicca Syndrome (Sjogren) (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Sicca Syndrome (Sjogren) (Immunology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Sicca Syndrome (Sjogren) (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Sicca Syndrome (Sjogren) (Immunology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Sicca Syndrome (Sjogren) (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Sicca Syndrome (Sjogren) - Overview
    Sicca Syndrome (Sjogren) - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Sicca Syndrome (Sjogren) - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Sicca Syndrome (Sjogren) - Companies Involved in Therapeutics Development
    Akari Therapeutics Plc
    Amgen Inc
    Atlantic Bio Sci LLC
    Bristol-Myers Squibb Company
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    Galapagos NV
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Immunwork Inc
    MedImmune LLC
    Novartis AG
    Redx Pharma Plc
    Samjin Pharmaceutical Co Ltd
    UCB SA
    XTL Biopharmaceuticals Ltd
    Sicca Syndrome (Sjogren) - Drug Profiles
    abatacept - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ABS-11 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AMG-557 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    belimumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    belimumab + rituximab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BMS-986142 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy for Type 1 Diabetes and Sjogrens Syndrome - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CFZ-533 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Coversin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    edratide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    filgotinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-9876 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2618960 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMSO-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    leniolisib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lulizumab pegol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-3090106 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MEDI-4920 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MEDI-7734 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RDX-002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RG-7625 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RSLV-132 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SA-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    seletalisib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TE-2324 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tirabrutinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VAY-736 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VM-200 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Sicca Syndrome (Sjogren) - Dormant Projects
    Sicca Syndrome (Sjogren) - Discontinued Products
    Sicca Syndrome (Sjogren) - Product Development Milestones
    Featured News & Press Releases
    Apr 05, 2017: XTL Biopharmaceuticals Unveils Expanded hCDR1 Preclinical Data for the Treatment of Sjogren's Syndrome
    Apr 04, 2017: Galapagos announces three new Phase 2 Proof-of-Concept studiesbwith filgotinib
    Feb 13, 2017: XTL Biopharmaceuticals Expands Clinical Advisory Board to Support Phase II Study of HCDR1 in Sjogren's Syndrome
    Jan 05, 2017: XTL Biopharmaceuticals' Preclinical Studies of hCDR1 Demonstrate Therapeutic Potental In the Treatment of Sjogren's Syndrome
    Apr 22, 2011: Breakthrough study links Type 1 diabetes and Sjogren's syndrome
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Sicca Syndrome (Sjogren) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Akari Therapeutics Plc, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Amgen Inc, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Atlantic Bio Sci LLC, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Eli Lilly and Company, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Galapagos NV, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Gilead Sciences Inc, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Immunwork Inc, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by MedImmune LLC, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Novartis AG, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Redx Pharma Plc, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by Samjin Pharmaceutical Co Ltd, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by UCB SA, H1 2017
    Sicca Syndrome (Sjogren) - Pipeline by XTL Biopharmaceuticals Ltd, H1 2017
    Sicca Syndrome (Sjogren) - Dormant Projects, H1 2017
    Sicca Syndrome (Sjogren) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Sicca Syndrome (Sjogren) , H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Top 10 Molecule Types, H1 2017
    Number of Products by Stage and Top 10 Molecule Types, H1 2017
    Akari Therapeutics Plc
    Amgen Inc
    Atlantic Bio Sci LLC
    Bristol-Myers Squibb Company
    Eli Lilly and Company
    F. Hoffmann-La Roche Ltd
    Galapagos NV
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    Immunwork Inc
    MedImmune LLC
    Novartis AG
    Redx Pharma Plc
    Samjin Pharmaceutical Co Ltd
    UCB SA
    XTL Biopharmaceuticals Ltd

    Request for Sample

    Report Url https://www.reportsweb.com//sicca-syndrome-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//sicca-syndrome-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//sicca-syndrome-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments